title: Clinical response of acneiform eruptions caused by cetuximab to administration of oral tetracycline and topical ketoconazole.
abstract: BACKGROUND
  Cutaneous adverse events associated with the use of epidermal growth factor receptor inhibitors, such as cetuximab are relatively common. Although there are reports about possible treatments for acne or acneiform lesions induced by cetuximab, there are only few reports of prospective studies.
  
  
  OBJECTIVE
  The aim of the study was to analyze the efficacy of varius treatment modalities and their combinations in patients with acneiform eruptions caused by cetuximab.
  
  
  METHODS
  We studied 14 patients treated with an epidermal growth factor receptor inhibitors, including 7 patients cetuximab, who developed acneiform eruptions in the course of therapy. All patients were diagnosed as grade II according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. A corticosteroid ointment, tacrolimus ointment, and ketoconazole ointment were used in a randomized manner. Oral therapy included administration of antihistaminic drugs, tetracycline, a cyclooxygenase inhibitor, or a macrolide. We measured the numer of days required to achieve improvement from grade II to grade I during cetuximab treatment.
  
  
  RESULTS
  Our results showed that tetracycline treatment may shorten the period needed to achieve improvement. Ketoconazole cream and a combination of oral tetracycline and topical ketoconazole also significantly shortened this period.
  
  
  CONCLUSIONS
  The results of our short case study may indicate that a combitation therapy of oral tetracyclin and topical ketokonazole is most effective in the therapy of patients with acneiform eruptions caused by cetuximab.
authors.affiliation: Department of Dermatology, Asahikawa Kousei Hospital, Asahikawa, Japan;
authors.forename: Satoshi
authors.initials: S
authors.lastname: Nakamura
authors.affiliation: Department of Dermatology, Asahikawa Kousei Hospital, Asahikawa, Japan;
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Hashimoto
authors.affiliation: Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan.
authors.forename: Kaoru
authors.initials: K
authors.lastname: Nishi
authors.affiliation: Department of Dermatology, Asahikawa Kousei Hospital, Asahikawa, Japan;
authors.forename: Tosihiro
authors.initials: T
authors.lastname: Mizumoto
authors.affiliation: Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan.
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Takahashi
authors.affiliation: Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan.
authors.forename: Hajime
authors.initials: H
authors.lastname: Iizuka
keywords: acne; adverse event; cetuximab; colon cancer; erlotinib; folliculitis; gefitinib; ketoconazole; panitumumab; tetracycline
references.citation: Acta Derm Venereol. 2008;88(1):84-6
references.pmid: 18176767
references.citation: Cancer Res. 2007 Oct 1;67(19):9380-8
references.pmid: 17909047
references.citation: Skin Therapy Lett. 2007 Jul-Aug;12(6):1-5
references.pmid: 17762902
references.citation: Cancer. 2008 Aug 15;113(4):847-53
references.pmid: 18543329
references.citation: Exp Dermatol. 2003 Aug;12(4):445-52
references.pmid: 12930301
references.citation: EMBO J. 1995 Nov 1;14(21):5216-23
references.pmid: 7489711
references.citation: Clin Exp Dermatol. 2007 Jan;32(1):71-4
references.pmid: 17034418
references.citation: J Clin Oncol. 2005 Aug 1;23(22):5235-46
references.pmid: 16051966
references.citation: Clin Colorectal Cancer. 2008 Jan;7(1):33-43
references.pmid: 18279575